

Supplemental Table 1 - Clinical characteristics of 90 patients with type 2 diabetes stratified for outcomes (survivors vs non survivors)

| | Survivors (n = 52) | Non survivors (n = 38) | P value |
|---|--------------------|------------------------|---------|
| M/F | 37 (71) / 15 (29) | 28 (74%) / 10 (26) | 0.370 |
| Age (yrs) | 69 (60-74) | 77 (71-82) | 0.001 |
| <u>Comorbidities</u> | | | |
| Hypertension | 36 (69) | 33 (86) | 0.051 |
| Obesity (BMI ≥ 30) | 24 (46.2) | 19 (50) | 0.718 |
| CAD | 15 (28.8) | 20 (52.5) | 0.022 |
| CKD | 6 (11.5) | 11 (28.9) | 0.037 |
| COPD | 5 (9.6) | 9 (23.7) | 0.069 |
| Stroke | 5 (9.6) | 10 (26) | 0.036 |
| Cancer | 7 (13.5) | 12 (31) | 0.038 |
| <u>Laboratory findings</u> | | | |
| Glycemia (mmol/L) | 8.7 ± 2.9 | 9.6 ± 3.9 | 0.220 |
| Creatinine (mg/dL) | 1.26 ± 1.82 | 1.79 ± 2.15 | 0.217 |
| eGFR (ml/min) | 82 ± 29 | 59 ± 28 | < 0.001 |
| Lymphocyte (x10^3/mm^3) | 1.2 ± 0.5 | 0.9 ± 0.5 | 0.024 |
| IL-6 (pg/mL) | 67 ± 48 | 115 ± 82 | 0.011 |
| D-Dimer (ng/mL) | 589 ± 964 | 1404 ± 2281 | 0.069 |
| LDH (U/L) | 300 ± 88 | 381 ± 166 | 0.005 |
| Ferritin (ng/mL) | 493 ± 380 | 854 ± 792 | 0.011 |
| CRP (mg/dL) | 9.6 ± 7.5 | 14 ± 8.4 | 0.037 |
| PCT (ng/mL) | 0.3 ± 0.7 | 0.72 ± 0.8 | 0.027 |
| <u>Medications</u> | | | |
| Lipid lowering drugs | 15 (28.8) | 14 (36.8) | 0.356 |
| Antiaggregant/anticoagulant | 21 (40.3) | 20 (52.6) | 0.186 |
| ACE-I/ARB | 24 (46.1) | 16 (42.1) | 0.965 |
| Ca-blockers | 13 (25) | 15 (39.4) | 0.067 |
| Beta-blockers | 13 (25) | 20 (52.6) | 0.002 |
| Diuretics | 12 (23) | 13 (34.2) | 0.135 |
| <u>Glucose lowering medication</u> | | | |

| | | | |
|-------------------------------------|-----------|-----------|-------|
| Insulin | 10 (19.2) | 19 (50) | 0.002 |
| Metformin | 44 (84.6) | 25 (65) | 0.037 |
| Sulfonylureas | 7 (13.4) | 3 (7.8) | 0.407 |
| DPP4-I | 10 (19.2) | 1 (2.6) | 0.018 |
| GLP-1 RA | 6 (11.5) | 0 | 0.030 |
| SGLT2-I | 2 (3.8) | 3 (7.8) | 0.408 |
| Pioglitazone | 1 (1.9) | 0 | 0.390 |
| <u>O₂ therapy</u> | | | |
| Supplemental Oxygen | 25 (48) | 15 (39.4) | 0.098 |
| Mechanical non-invasive ventilation | 9 (17.3) | 16 (42.1) | 0.019 |
| Invasive ventilation | 1 (1.9) | 6 (15.7) | 0.006 |

Categorical data were presented as n/n or n (%), continuous data were presented as either mean \pm SD or median and interquartile range (IQR).

CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DPP4-I, dipeptidyl peptidase 4 inhibitors; SGLT2-I, sodium–glucose cotransporter 2 inhibitors; GLP-1 RA, glucagon-like peptide 1 Receptor Agonists, IL-6, interleukin-6; LDH, lactate dehydrogenase CRP, C-reactive protein; PCT, procalcitonin.